Lumida
/CDNA
⌘K
CareDx Inc

CareDx Inc

CDNA
$39.73USD↓-1.51%-0.61 today

MARKET CAP

2.1B

P/E (TTM)

47.3x

FWD P/E

46.6x

DAY RANGE

$38 – $40

52W RANGE

$11
$40

AI Summary

Stalk
StalkMedium

CDNA remains in a Stage 2 advance within an intact long-term uptrend; despite an extreme overbought peak, no active reversal patterns are present and medium-term bias stays bullish. However, price is still extended above the rising EMAs, so immediate entries are less favorable. We will stalk for a clear pullback into the 9- and 21-day EMA support zone before buying. Key risks include a failed pullback that turns into a deeper correction or a prolonged extension that delays entry.

  • ↑Q1 2026 revenue of $118 M (+39% YoY); testing services revenue $91 M (+48% YoY).
  • ↑Adjusted EBITDA $19 M (+300% YoY) driven by record cash realizations from RCM.
  • ↓Potential $15 M headwind from proposed LCD reimbursement cuts.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

CareDX, Inc. (NASDAQ: CDNA) is a precision diagnostics company specializing in solutions for transplant patients, particularly in organ transplantation. The firm focuses on non-invasive testing and digital platforms, enhancing patient outcomes and clinician workflows. CareDX is strategically positioned to capitalize on the growing need for transplant diagnostics, leveraging advanced technologies and strong market relationships in the transplant segment.

Bull says

  • ↑Q1 2026 revenue of $118 M (+39% YoY); testing services revenue $91 M (+48% YoY).
  • ↑Adjusted EBITDA $19 M (+300% YoY) driven by record cash realizations from RCM.
  • ↑2026 guidance raised to $447–465 M revenue (+20% YoY); test volumes 224K–229K (+13% YoY).
  • ↑AlloSure Plus launch and market leadership in transplant diagnostics boost moat.
  • ↑Nevaris acquisition expands molecular portfolio into specialty oncology markets.
  • ↑Strong factor profile: high earnings revisions, robust growth, improved profitability & liquidity.

Bear says

  • ↓Potential $15 M headwind from proposed LCD reimbursement cuts.
  • ↓Unpredictable transplant volumes risk growth stability, per CEO commentary.
  • ↓High volatility poses price‐stability concerns amid market fluctuations.
  • ↓Insider selling and 32% jump in short interest reflect waning investor sentiment.
  • ↓Elevated leverage and interest‐rate sensitivity could strain financial flexibility.
  • ↓Weak valuation metrics: poor earnings yield, low book‐to‐price and limited institutional interest.

Investment themes with CDNA

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 04-29-2026bullish

Transcript signals

Bull points

  • we feel very comfortable with the 30% to 40% growth rate going forward, and that's why we provided commentary that we anticipate that to persist over the next three years.
  • we still think there's substantial runway in kidney. We continue to see growth in heart care, and in particular, Alimap as a product growing sequentially quarter over quarter, even after being on the market for over 20 years now, which is incredibly impressive.
  • today we feel really confident in the portfolio that the company has, and it is the market leader in both head and neck and anal cancers.

Bear points

  • Lab products revenue declined 4% to 10 million
  • the LCD to negatively impact revenue, not volume, by $7.5 million in the second half of 2026
Read full transcript analysis ›